GlassScriptPhysician profile
Nestor Delgado
NPI 1568438117
$1,262.57
in general payments reported to CMS, 2019-2025
22 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $13.50 · 2022: $161 · 2023: $425 · 2024: $235 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $753 · Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.38 |
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $268.71 | 2019-2023 | Liletta, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $187.08 | 2022-2025 | |
| Baxter Healthcare | $116.75 | 2024 | Perclot |
| Minerva Surgical, INC | $106.53 | 2019 | |
| Hologic Sales and Service, LLC | $87.39 | 2020-2025 | Myosure Tissue Removal Device, Aptima, Fluent Fluid Management System |
| Astellas Pharma US INC | $86.86 | 2023 | Myrbetriq |
| Organon LLC | $81.75 | 2022-2025 | Jada System |
| Takeda Pharmaceuticals U.S.A., INC. | $49.86 | 2019 | |
| Amgen INC. | $45.57 | 2019-2023 | Evenity, Prolia |
| Sage Therapeutics, LLC | $32.89 | 2024-2025 | Zurzuvae |
| Becton, Dickinson and Company | $25.97 | 2024 | Bd Max System, Bd Max Instrument |
| Millicent US INC | $21.06 | 2025 | Femlyv |
| Ardelyx, INC. | $18.66 | 2023 | Ibsrela |
| Mallinckrodt Enterprises LLC | $17.97 | 2019 | |
| Smith+Nephew, INC. | $17.27 | 2024 | Renasys Touch, Pico 7 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.76 | 2019 | |
| Evofem Biosciences, INC. | $16.59 | 2023 | Phexxi |
| Ethicon US, LLC | $14.82 | 2025 | Enseal, Endopath Xcel |
| Coopersurgical, INC. | $14.27 | 2023 | Paragard T 380a |
| Boston Scientific Corporation | $12.74 | 2019 | |
| Therapeuticsmd, INC. | $12.15 | 2022 | |
| Amag Pharmaceuticals, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nestor Delgado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.